Tonix Pharmaceuticals (TNXP) Stock Climbs On Study Completion

Tonix Pharmaceuticals TNXP Stock News

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) is making its way to the top int he market this morning after announcing the successful completion of a clinical study. As a result of the news the stock is up just shy of 40% early on in the market today. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

TNXP Stock Climbs On Study Completion

In a press release issued this morning, Tonix Pharmaceuticals said that it has completed a required study. The study surrounded fed-fasting and dose proportionality testing of TNX-102 SL in healthy volunteers. 

In the release, TNXP said that the study was required for the New Drug Application of TNX-102 SL for the treatment of PTSD and fibromyalgia. 

Importantly, the company said that the results of the study showed no significant effect of a fatty meal on the rate or extent of absorption of TNX-102 SL 5.6 mg administered as 2 x 2.8 mg sublingual tablets. 

Why This News Is Important

Ultimately, food effects that change the plasma drug levels can add a level of unpredictability for patients. This is true in both, therapeutic benefit and side effects. 

The fact that TNXP showed that TNX-102 SL has an absense of a food effect is great news. This means that the unpredictability associated with food and medicine is not an issue here. 

As a result, there’s a strong chance that the company will be able to move forward with a New Drug Application, potentially bringing TNX-102 to the market. 

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story!

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.